Bayer announced that the US Food and Drug Administration accepted its supplemental application for Kerendia in non-diabetic chronic kidney disease. The announcement creates a potential new treatment opportunity for patients whose kidney disease develops without diabetes. The Kerendia Expansion could address an important gap in care, where treatment options remain limited for many patients. The application follows positive Phase III FIND-CKD trial results, which evaluated finerenone alongside standard treatment in adults with chronic kidney disease.
Kerendia Expansion Targets an Underserved Kidney Patient Population
The FIND-CKD study enrolled 1,584 adults with chronic kidney disease who did not have diabetes. Researchers compared finerenone against placebo alongside standard care. The trial met its primary endpoint, demonstrating a statistically significant improvement in estimated glomerular filtration rate decline. This measurement helps clinicians assess how kidney function changes over time. The Kerendia Expansion is supported by evidence showing a slower rate of kidney function decline, although the proposed indication remains under regulatory review.
The trial also reported a statistically significant reduction in a combined kidney and cardiovascular outcome. This measure included kidney failure, substantial sustained kidney-function decline, heart-failure hospitalization, or cardiovascular death. The findings matter because chronic kidney disease can affect both renal function and cardiovascular health. The Kerendia Expansion could therefore become commercially important if regulators approve the additional indication. However, the trial findings do not guarantee approval or establish identical benefits for every patient.
Kerendia, whose active ingredient is finerenone, already has established US indications. These include certain kidney and cardiovascular risks associated with type 2 diabetes, alongside specific heart-failure treatment. In September 2026, the FDA also approved its use for adults with chronic kidney disease associated with type 1 diabetes. The latest application extends Bayer’s strategy into non-diabetic kidney disease. The Kerendia Expansion could broaden the medicine’s eligible population, depending on the eventual FDA decision and approved prescribing information.
For patients, an additional treatment option could offer meaningful value if future approval confirms its benefit-risk profile. Healthcare providers will need to consider kidney function, potassium levels, existing medicines, and individual clinical circumstances. Kerendia can increase blood potassium, making appropriate laboratory monitoring important. For Bayer, the application strengthens its position in kidney medicine and could expand the product’s addressable market. The Kerendia Expansion now depends on FDA review, with final availability determined by the agency’s decision.
